Interleukin-1 (IL-1), a multifunctional cytokine, induces the synthesis of regulatory molecules which effect endothelial cells, macrophages, T cells and other accessory cells. The applicant has demonstrated previously that IL-la induces acute tumor hemorrhagic necrosis, changes in tumor blood flow and increases clonogenic tumor cell kill. Under support of this grant, they have demonstrated that IL-la significantly enhances cisplatin (cDDP) and carboplatin (CBDCA) anti- tumor activities with time-dependent differences. To minimize toxicity, IL-la was administered by low dose continuous infusion and shown to maintain enhanced CBDCA anti-tumor effects and diminished CBDCA- induced thrombocytopenia. Using a method developed in the applicant's laboratory for the isolation of freshly derived tumor endothelial cells, they have demonstrated that IL-la/ interferon-g (IFN-g) (acytokine induced in the tumor after IL-la) induces a significant level of NO as compared to normal endothelial cells. Tumor-endothelial cells also express increased levels of message for entactin, an extracellular matrix protein. Lastly, IL-la significantly enhanced anti-tumor efficacy of cyclophosphamide (CTX) alone, CTX/CBDCA or CBDCA/etoposide (VP-16).
The aims of this study are: 1) to characterize endothelial cells isolated from untreated and IL-la treated tumor-bearing mice with normal endothelial cells with respect to proliferative response, cellular adhesion molecule (CAM) expression, the ability to synthesize matrix metalloproteinases; 2) to determine whether NO production by tumor-derived endothelial cells contributes to IL-1a induced anti-tumor effects and potentiation of platinum-mediated anti-tumor activities; 3) to determine whether a relationship exists between gene expression of entactin, an extracellular matrix protein, and IL-1a induced effects on tumor endothelium in vitro and in vivo and 4) to examine the ability of IL-la to enhance the therapeutic efficacy of CBDCA in combination with VP-16. These studies will provide the groundwork for the use of IL-1 or related cytokines either alone or in combination with cytotoxic drugs for the therapy of solid tumors.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG2-ET-1 (01))
Program Officer
Hecht, Toby T
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
Schools of Medicine
United States
Zip Code
Yu, W D; Chang, M J; Trump, D L et al. (1997) Interleukin-1alpha synergistic in vivo enhancement of cyclophosphamide- and carboplatin-mediated antitumor activity. Cancer Immunol Immunother 44:316-22
McElwain, M C; Modzelewski, R A; Yu, W D et al. (1997) Vitamin D: an antiproliferative agent with potential for therapy of squamous cell carcinoma. Am J Otolaryngol 18:293-8
Chang, M J; Modzelewski, R A; Russell, D M et al. (1996) Interleukin 1 alpha and gamma-interferon induction of nitric oxide production from murine tumor-derived endothelial cells. Cancer Res 56:886-91
Grandis, J R; Chang, M J; Yu, W D et al. (1995) Antitumor activity of interleukin-1 alpha and cisplatin in a murine model system. Arch Otolaryngol Head Neck Surg 121:197-200
Chang, M J; Yu, W D; Reyno, L M et al. (1994) Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model. Cancer Res 54:5380-6
Modzelewski, R A; Davies, P; Watkins, S C et al. (1994) Isolation and identification of fresh tumor-derived endothelial cells from a murine RIF-1 fibrosarcoma. Cancer Res 54:336-9
Johnson, C S; Chang, M J; Yu, W D et al. (1993) Synergistic enhancement by interleukin-1 alpha of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ mice. Cancer Chemother Pharmacol 32:339-46
Chang, M J; Pourbohloul, S C; Yu, W D et al. (1992) Differential effect in vitro of tumor necrosis factor-alpha (TNF) on normal and virus-infected erythroid progenitors from Friend virus (FVA)-infected mice. Exp Hematol 20:1271-7
Braunschweiger, P G; Jones, S A; Johnson, C S et al. (1991) Interleukin-1 alpha-induced tumour pathophysiologies can be exploited with bioreductive alkylating agents. Int J Radiat Biol 60:369-72
Braunschweiger, P G; Jones, S A; Johnson, C S et al. (1991) Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1 alpha. Cancer Res 51:5454-60

Showing the most recent 10 out of 21 publications